VTRO (Vitro Biopharma) ROC %: -297.99% (As of Oct. 2022)

What is Vitro Biopharma ROC %?

Vitro Biopharma VTRO ROC % is -297.99% as of Oct. 2022. The stock has 6 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Vitro Biopharma's annualized return on capital (ROC %) for the quarter that ended in Oct. 2022 was -297.99%.

As of today (2026-06-26), Vitro Biopharma's WACC % is 7.97%. Vitro Biopharma's ROC % is -74.50% (calculated using TTM income statement data). Vitro Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Vitro Biopharma (AMEX:VTRO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Vitro Biopharma's WACC % is 7.97%. Vitro Biopharma's ROC % is -74.50% (calculated using TTM income statement data). Vitro Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Vitro Biopharma ROC % Related Terms

Vitro Biopharma ROC % Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma ROC % Chart

Vitro Biopharma Annual Data

Trend

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

Oct17

Oct21

Oct22

ROC %

Get a 7-Day Free Trial

-11.28

-13.81

-39.02

-110.84

-74.50

Vitro Biopharma Quarterly Data
	Oct00	Oct01	Oct02	Oct03	Oct04	Oct05	Oct06	Oct07	Oct08	Oct09	Oct10	Oct11	Oct12	Oct13	Oct14	Oct15	Oct17	Oct21	Oct22
ROC %	Get a 7-Day Free Trial														-45.10	-55.22	-156.10	-443.34	-297.99

Vitro Biopharma ROC % Calculation

Vitro Biopharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Oct. 2022 is calculated as:

	ROC % (A: Oct. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Oct. 2021 )	+	Invested Capital (A: Oct. 2022 ))	/ count )
=	-5.052 * ( 1 - 0% )	/	( (7.162	+	6.401)	/ 2 )
=	-5.052	/	6.7815
=	-74.50 %

where

	Invested Capital		(A: Oct. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.129	-	0.754	-	( 3.627	-	max(0, 1.423	-	4.636	+	3.627	))
=	7.162

	Invested Capital		(A: Oct. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.574	-	1.777	-	( 0.742	-	max(0, 2.54	-	2.936	+	0.742	))
=	6.401

Vitro Biopharma's annualized Return on Capital (ROC %) for the quarter that ended in Oct. 2022 is calculated as:

	ROC % (Q: Oct. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2021 )	+	Invested Capital (Q: Oct. 2022 ))	/ count )
=	-20.208 * ( 1 - 0% )	/	( (7.162	+	6.401)	/ 2 )
=	-20.208	/	6.7815
=	-297.99 %

where

	Invested Capital		(Q: Oct. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.129	-	0.754	-	( 3.627	-	max(0, 1.423	-	4.636	+	3.627	))
=	7.162

	Invested Capital		(Q: Oct. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.574	-	1.777	-	( 0.742	-	max(0, 2.54	-	2.936	+	0.742	))
=	6.401

Note: The Operating Income data used here is four times the quarterly (Oct. 2022) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -297.99% mean?

Vitro Biopharma (VTRO) has a ROC % of -297.99% as of Oct. 2022. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Vitro Biopharma and its competitors.

Is Vitro Biopharma's ROC % too high?

Vitro Biopharma's current ROC % is -297.99%.

How does Vitro Biopharma's ROC % compare to ?

Vitro Biopharma's ROC % of -297.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current ROC % is -297.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vitro Biopharma stock overvalued right now?

Vitro Biopharma (VTRO) has a current ROC % of -297.99%. The current ROC % is -297.99%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current ROC % is -297.99% as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies

Address 4621 Technology Drive, Golden, CO, USA, 80403

Website http://www.vitrobiopharma.com

Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.